Drugs / IVL3001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04945226 | Sep 2021 → Feb 2022 | androgenetic alopecia | Inventage Lab., Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IVL3001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04945226 ↗ |
| Action | Inhibit | “Consistent with its mechanism of action, IVL3001 reduced DHT levels.” PMID 38833144 ↗ Jun 2024 |
| Route | Subcutaneous | “the IVL3001 group received a single subcutaneous injection of 12-36 mg IVL3001” PMID 38833144 ↗ Jun 2024 |